Updated Story FDA’s drug center is striving to keep up with innovation in medical technology and an increased amount of data to analyze around regulatory decisions for drugs, according to its director, who promotes initiatives that ramp up a focus on quantitative data analysis, encourage innovative clinical trial approaches and make sure its advisory committees are fit for purpose. In an interview with Inside Health Policy , Center for Drug Evaluation and Research (CDER) Director Patrizia Cavazzoni...